Catalog No.
Product Name
Application
Product Information
Citations
-
Calcium/Sodium Channel Blocker
Elpetrigine is a potent calcium and sodium channel blocker with significant anticonvulsant, antidepressant, antimania, and anxiolytic properties. This compound is primarily utilized in research focused on epilepsy and bipolar disorder, contributing to the understanding of neurological and mood disorders. Its mechanism of action makes it a valuable tool for exploring therapeutic avenues in these conditions. -
N-type Calcium Channel Antagonist
Huwentoxin XVI is a selective antagonist of N-type calcium channels, demonstrating a potent inhibitory effect with an IC50 of approximately 60 nM. Derived from the Chinese tarantula Ornithoctonus huwena, it serves as an analgesic and exhibits no activity against voltage-gated T-type calcium channels, potassium channels, or sodium channels. This specificity makes Huwentoxin XVI valuable in research aimed at understanding pain mechanisms and the role of calcium channels in various physiological processes. -
Broad-Spectrum Antiepileptic Agent
JNJ-26990990 is a broad-spectrum antiepileptic agent that primarily targets voltage-gated sodium channels and N-type calcium channels. It exhibits significant anticonvulsant activity, making it suitable for the study of various seizure models. Although it shows minimal inhibition of human carbonic anhydrase-II with an IC50 of 110 μM, its primary applications lie in the investigation of epilepsy and related neurological disorders. -
Sodium/Calcium Channel Blocker
KT 2-230 is a sodium and calcium channel blocker that exhibits significant anti-inflammatory properties. This compound is utilized in research applications focused on neuropathic pain and various inflammatory conditions. Its ability to modulate ion channel activity makes it a valuable tool for studying the underlying mechanisms of synaptic transmission and neuroprotection. -
Sodium Channel Blocker
CAY10568 is a sodium channel blocker that modulates neuronal excitability. This compound, a derivative of QX-314, exhibits a smaller and less hydrophobic profile, making it suitable for exploring its effects on inflammation and pain perception. CAY10568 is valuable for research applications aimed at understanding pain mechanisms and developing analgesic therapies. -
Sodium Channel Inhibitor
(-)-Sparteine sulfate pentahydrate is a sodium channel inhibitor that acts as a class 1a antiarrhythmic agent. It has demonstrated notable biological activity in modulating cardiac excitability and can be utilized in research focusing on arrhythmias and pharmacological studies related to ion channel function. This reagent is suitable for investigating the effects of sodium channel blockade in various biological models. -
Nav1.7 Inhibitor
Nav1.7-IN-6 is a selective inhibitor targeting the voltage-gated sodium channel Nav1.7, which is important in pain signaling pathways. This compound demonstrates significant biological activity in modulating neuronal excitability, making it a valuable tool for research on pain mechanisms and potential therapeutic interventions in pain disorders. Its specificity for Nav1.7 enhances its utility in elucidating the role of this channel in nociception and related studies. -
NaV1.7 Antagonist
AMG8379 is a selective sulfonamide antagonist targeting the voltage-gated sodium channel NaV1.7. It demonstrates potent inhibition with IC50 values of 8.5 nM for human NaV1.7 and 18.6 nM for mouse NaV1.7, effectively blocking TTX-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC50 of 3.1 nM. This compound is useful for research applications related to pain pathways and sodium channel modulation. -
Sodium Channel Inhibitor
B-GYKI-38233 hydrochloride is a sodium channel inhibitor that exhibits potent antiarrhythmic properties. This compound is utilized in research focused on the modulation of sodium channels, which play a critical role in cardiac excitability and conductivity. Its mechanism of action makes it a valuable tool for the investigation of arrhythmias and related cardiovascular disorders. -
Nav1.8 channel Inhibitor
Nav1.8-IN-10 is a selective inhibitor of the Nav1.8 ion channel. At a concentration of 4 nM, it achieves an impressive blocking rate of 79.4%, demonstrating its potency. This compound is primarily utilized in the research of pain disorders, facilitating investigations into the modulation of pain pathways and potential therapeutic interventions. -
Nav1.8 Inhibitor
Nav1.8-IN-5 is a selective inhibitor of the voltage-gated sodium channel Nav1.8. It demonstrates potent biological activity against Nav1.8-mediated pain and pain-related disorders, making it a valuable tool for research in these areas. Additionally, Nav1.8-IN-5 can facilitate studies related to cardiovascular diseases, including conditions such as atrial fibrillation, by modulating sodium channel activity. -
Sodium Channel Inhibitor
R 59494 is a sodium channel inhibitor that effectively blocks Na+ and Ca2+ uptake triggered by veratridine exposure. This compound exhibits significant anti-ischemic properties, making it valuable for research in cardiovascular and neuroprotective studies. Its ability to modulate ion channel activity positions R 59494 as a useful tool for investigating the mechanisms of ischemia-related cellular damage. -
Nav1.7 Blocker
NAV 26 is a selective blocker of the voltage-gated sodium channel Nav1.7, exhibiting an IC50 of 0.37 μM. This compound is valuable for investigating pain mechanisms and developing novel analgesics. Its specificity for Nav1.7 makes it a crucial tool in researching pain pathways and potential therapeutic interventions. -
NaV1.8 Channel Inhibitor
Analgesic agent-2 is a selective NaV1.8 channel inhibitor, exhibiting a reported IC50 of 50.18 nM in HEK293 cells expressing the human NaV1.8 channel. It demonstrates significant analgesic activity, making it a valuable tool for pain research. This compound is ideal for studies investigating the role of NaV1.8 in nociception and the development of novel analgesic therapies. -
Nav1.8 Inhibitor
Nav1.8-IN-15 is a potent inhibitor of the voltage-gated sodium channel Nav1.8. It demonstrates significant analgesic effects and is relevant for research exploring pathways involved in chronic pain management. This compound can facilitate the study of Nav1.8's role in pain signaling and aid in the development of novel therapeutic strategies for pain relief. -
NaV1.7 Antagonist
AMG8380 is a selective antagonist of the voltage-gated sodium channel NaV1.7, exhibiting IC50 values of 0.907 µM and 0.387 µM in human and mouse tissues, respectively. This compound effectively inhibits Tetrodotoxin (TTX)-sensitive native channels with an IC50 of 2560 nM, making it a valuable tool for research on pain pathways and sodium channel function. Its properties allow for exploration of NaV1.7's role in nociception and related applications in pharmacological studies. -
NaV1.7 Inhibitor
Sodium Channel-IN-7 is a selective inhibitor of the NaV1.7 voltage-gated sodium channel. It interacts with the voltage-sensor domain 4 (VSD4) binding pocket of NaV1.7, demonstrating limited interaction with residue Try1537. This compound is primarily utilized in research focused on pain mechanisms and pain-related disorders. -
Sodium Channel Inhibitor
Cofirasersen is a sodium channel inhibitor that targets the epithelial sodium channel (ENaC). It is specifically developed to downregulate ENaC expression in the lungs, where hyperactivity of ENaC is implicated in cystic fibrosis, a disorder linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This compound has potential applications in research related to cystic fibrosis and the modulation of sodium transport in pulmonary tissues. -
Nav1.7 Antagonist
Nav1.7-IN-15 is a potent state-dependent antagonist of the sodium channel Nav1.7, exhibiting an IC50 of 0.42 μM for human Nav1.7 PX. This compound is valuable for studying pain mechanisms and is useful in research focusing on neuropathic pain and other conditions associated with Nav1.7 activity. Its ability to selectively inhibit Nav1.7 makes it an important tool for investigating the therapeutic potential of sodium channel modulation. -
NaV1.7 Inhibitor
PF-06456384 is a potent and selective inhibitor of NaV1.7, exhibiting an IC50 of 0.01 nM. This compound is primarily utilized in research involving pain mechanisms, particularly in formalin pain model studies, to elucidate the role of NaV1.7 in nociceptive signaling. Its high selectivity makes it an important reagent for exploring therapeutic strategies targeting chronic pain conditions. -
Sodium Channel Inhibitor
Nav1.8-IN-1 is a selective inhibitor of the Na(v)1.8 sodium channel, demonstrating significant potency in blocking its activity. This compound is particularly relevant for research focused on inflammatory and neuropathic pain pathways, providing valuable insights into pain mechanisms and potential therapeutic strategies. Its ability to modulate sodium channel function makes it a promising tool for understanding pain-related conditions. -
Sodium Channel Blocker
BW-4030W92 is a selective sodium channel blocker that inhibits sodium ion influx. This compound is utilized in research to study the role of sodium channels in neuronal excitability and can induce ataxia, providing insights into neurological disorders. Its application is significant in pharmacological studies aiming to investigate the mechanisms of action of sodium channel modulation. -
NaV Modulator
Clathrodin is a marine alkaloid derived from Agelas sponges that functions as a modulator of voltage-gated sodium (NaV) channels. As a sodium channel neurotoxin, Clathrodin impacts sodium channel ionic conductance, making it a valuable tool for studying excitability in neurons and muscle cells. This reagent is useful in research applications involving neuropathic pain, neurotoxicity assessments, and the physiological characterization of sodium channel function. -
Sodium Channel Blocker
Olisutrigine bromide is a potent sodium channel blocker that exhibits significant analgesic properties. This compound is primarily utilized in research focused on pain modulation and the investigation of sodium channel dynamics in neurological disorders. Its efficacy in inhibiting sodium influx makes it a valuable tool for exploring therapeutic interventions in pain management. -
Sodium Channel
Tolperisone is a centrally acting muscle relaxant that primarily targets sodium channels, leading to neuronal inhibition. It is effective in alleviating symptoms of spasticity and muscle spasms, making it a valuable tool in neuromuscular research and therapeutic studies. Tolperisone's mechanism of action extends its application in exploring muscle relaxation pathways and their implications in various neurological conditions. -
NaV1.7 Inhibitor
DS43260857 is a selective inhibitor of the sodium channel NaV1.7, exerting strong inhibitory effects on both human and mouse variants of the channel. It demonstrates IC50 values of 6.6 μM for hNaV1.1, 14 μM for hNaV1.5, 0.015 μM for hNaV1.7, and 0.061 μM for mNaV1.7. This compound is useful for investigating pain pathways and assessing the role of NaV1.7 in nociception-related research. -
Nav1.7 Inhibitor
PF 05089771 tosylate is a selective Nav1.7 inhibitor, known for its potent biological activity with IC50 values of 11 nM for human Nav1.7 and varying efficacy across other species. This arylsulfonamide compound is orally active, making it a valuable tool for investigating pain and diabetic neuropathy mechanisms in preclinical research. Its specificity for Nav1.7 highlights its potential application in developing novel analgesic therapies. -
Nav1.8 Inhibitor
Nav1.8-IN-18 is a selective inhibitor of the voltage-gated sodium channel Nav1.8. It exhibits significant activity in modulating neuronal excitability, making it a valuable tool for investigating pain pathways and sensory neuron function. This compound is suited for research applications focused on chronic pain models and neuropathic conditions. -
Sodium Channel Inhibitor
P552-02 mesylate is a sodium channel inhibitor that demonstrates significant potential for the treatment of cystic fibrosis. Its primary mechanism involves enhancing mucociliary clearance in the lungs, contributing to improved respiratory function. Additionally, P552-02 mesylate minimizes the risk of hyperkalaemia, making it a valuable compound for researchers studying respiratory diseases and therapeutic interventions. -
Nav1.7 Inhibitor
QLS-81 is a selective inhibitor of the Nav1.7 ion channel, demonstrating an inhibition constant (IC50) of 1.5 μM. This compound exhibits potent analgesic properties, effectively alleviating both neuropathic and inflammatory pain. By targeting the inactivated state of Nav1.7 channels, QLS-81 mediates frequency-dependent inhibition, making it a valuable tool for research focused on chronic pain mechanisms and potential therapeutic interventions. -
Sodium Channel Inhibitor
Nav1.8-IN-20 is a potent inhibitor of the voltage-gated sodium channel Nav1.8, demonstrating an IC50 value of 14 nM. By blocking the generation and conduction of action potentials in peripheral nociceptive neurons, it exerts significant analgesic effects. This compound is valuable for research into various pain models, including acute pain, chronic pain, inflammatory pain, and neuropathic pain. -
Sodium Channel Blocker
Nav1.7 blocker 1 is a selective sodium channel blocker that exhibits an IC50 value of 0.037 μM against the Nav1.7 target. This compound is primarily utilized in pain research, making it valuable for investigating various pain conditions, including neuropathic pain, postoperative pain, and inflammatory pain. Its potent activity allows for the exploration of mechanisms underlying pain signaling and the development of potential therapeutic strategies. -
Nav1.8 channel Inhibitor
Nav1.8-IN-11 is a potent inhibitor of the Nav1.8 sodium channel, exhibiting an IC50 value of 0.1 nM. This compound is valuable for investigating pain disorders, as it modulates neuronal excitability and may provide insight into the underlying mechanisms of pain signaling and management. Research applications include exploring therapeutic strategies for chronic pain conditions. -
Sodium Channel Inhibitor
L589420-0-2 is a sodium channel inhibitor that modulates intracellular sodium ion concentrations, ultimately influencing the electrophysiological properties of cells. This compound demonstrates specific inhibitory activity in human erythrocytes and can be instrumental in studies related to cardiovascular disease. Its ability to affect sodium ion dynamics makes it a valuable tool for research in cellular biology and pharmacology. -
Sodium Channel
Nifedipine hydrochloride is a calcium channel blocker that primarily targets voltage-gated sodium channels. This compound demonstrates significant vasodilatory effects, making it effective as an antianginal agent and for lowering blood pressure. Nifedipine hydrochloride is extensively utilized in biological research to investigate new antihypertensive and antianginal therapies, contributing to the development of novel cardiovascular treatments. -
Nav1.8 Inhibitor
Nav1.8-IN-13 is a selective inhibitor of the voltage-gated sodium channel Nav1.8, with a reported pIC50 of 7.9. This compound is utilized in research to investigate the role of Nav1.8 in pain signaling pathways and neuronal excitability. Its inhibitory properties make it a valuable tool for studying potential therapeutic approaches for pain management and related neurological disorders. -
NaV1.7 Antagonist
GpTx-1 is a peptide-derived antagonist of the NaV1.7 sodium channel, extracted from the venom of the Chilean spider Grammostola porteri. It exhibits potent inhibitory activity with an IC50 of 10 nM specifically for the NaV1.7 channel, demonstrating substantial selectivity for NaV1.4 (IC50 = 0.301 μM) and NaV1.5 (IC50 = 4.20 μM), highlighting greater than 20-fold and over 950-fold selectivity, respectively. GpTx-1 is valuable in research applications focused on pain modulation and neurological disorders linked to NaV1.7 channel activity. -
nNav1.5 blocker
VGSC blocker-1 is a selective blocker of the neonatal voltage-gated sodium channel subtype Nav1.5 (nNav1.5). This small molecule inhibits peak sodium currents by 34.9% at a concentration of 1 μM, and it demonstrates a significant reduction in cell invasion by 0.3% at the same concentration in the MDA-MB-231 human breast cancer cell line, all while maintaining cell viability. VGSC blocker-1 is valuable for research into mechanisms of cancer metastasis and ion channel function in cellular processes. -
Nav1.5 Channels Blocker
Jingzhaotoxin-III is a highly selective blocker of Nav1.5 sodium channels, exhibiting an IC50 of 348 nM with no significant impact on other sodium channel isoforms. This toxin selectively inhibits the activation of cardiac sodium channels, making it a valuable tool for research focused on cardiac physiology and pathophysiology. Its specificity for the cardiac VGSC subtype positions Jingzhaotoxin-III as an important ligand for studies related to cardiovascular health and disease. -
Sodium Channel Blocker
Aneratrigine hydrochloride is a potent blocker of the sodium channel protein type 9 subunit alpha. This compound exhibits significant efficacy in modulating sodium channel activity, making it a valuable tool for research on neuropathic pain conditions. Its ability to inhibit excitatory neuronal signaling positions Aneratrigine hydrochloride as a promising reagent for studying pain pathways and potential therapeutic interventions. -
Sodium Channel Blocker
Ceratotoxin-2 is a potent blocker of voltage-gated sodium channels, exhibiting IC50 values of 8 nM and 88 nM against Nav1.2/β1 and Nav1.3/β1, respectively. This compound is valuable for investigating sodium channel-related physiological processes and studying disorders associated with sodium channel dysfunction. Its high specificity makes it an essential tool for research in neurobiology and pharmacology, facilitating the development of targeted therapies. -
Nav1.8 channel Inhibitor
Nav1.8-IN-12 is a selective inhibitor of the Nav1.8 sodium channel, known to play a crucial role in transmitting pain signals. This compound is valuable for investigating various pain-related diseases and disorders, facilitating the development of therapeutic strategies targeting neuropathic pain and inflammatory conditions. -
Voltage-Gated Sodium Channel Blocker
Proparacaine is a local anesthetic that functions as a voltage-gated sodium channel blocker. By inhibiting these channels on neuronal cell membranes, Proparacaine effectively disrupts signal conduction and reduces nociceptive signal transmission. This reagent is specifically utilized in ocular research, particularly in studies involving cataracts, to facilitate ocular muscle relaxation and minimize eye movement during surgical procedures. -
Sodium Channel Blocker
ACC-9358 is an orally active sodium channel blocker that exerts antiarrhythmic activity. This compound is valuable for research on cardiovascular diseases, particularly in the study and treatment of arrhythmias. Its mechanism of action and effects on sodium channels make it a useful reagent for understanding cardiac electrophysiology and developing therapeutic strategies. -
Sodium Channel Inhibitor
Oe-9000 is a sodium channel inhibitor that demonstrates local anesthetic activity by effectively blocking voltage-gated Na+ currents in neurons. It targets both TTX-sensitive and TTX-resistant currents, showing enhanced performance compared to other local anesthetics. This compound is valuable for research applications in pain management and neuropharmacology. -
Sodium Channel Blocker
Silperisone hydrochloride is a sodium channel blocker that exhibits centrally acting muscle relaxant properties. This compound selectively inhibits sodium and calcium channels, leading to decreased muscle cell excitability and contraction, which facilitates muscle relaxation and peripheral vasodilation. Silperisone hydrochloride is employed in research on recurrent painful myoclonus post-spinal cord injury, abnormal hypertonia associated with cerebrovascular disease, symptoms of myotonia, pyramidal tonia syndrome, and myospasm related to multiple sclerosis and myelitis. -
Nav1.5 Inhibitor
Nav1.5-IN-1 is a selective inhibitor of the sodium channel Nav1.5, exhibiting an IC50 of 1.38 μM. With demonstrated selectivity over other Nav subtypes, it effectively reduces cardiac conduction in isolated rat hearts. This compound serves as a valuable tool for investigating the mechanisms underlying cardiac arrhythmias. -
Sodium Channel Inhibitor
E-0747 is a sodium channel inhibitor that specifically targets Na[+] channels in cardiomyocytes. By blocking these channels, E-0747 exhibits antiarrhythmic properties, making it valuable for research into cardiac function and arrhythmia management. This compound can be utilized in studies investigating the mechanisms of electrical conduction and the potential therapeutic effects on various cardiac disorders. -
Nav1.8 Inhibitor
Nav1.8-IN-21 is a selective inhibitor of the Nav1.8 sodium channel, known for its role in transmitting pain signals. This compound exhibits significant analgesic activity and is valuable for research applications focused on pain management and neurophysiology. Its targeted inhibition makes it a useful tool for understanding the mechanisms of nociception and developing novel pain therapeutics. -
Nav1.2 Inhibitor
Nav1.2-IN-1 is a selective inhibitor of the Nav1.2 sodium channel, characterized by its structure as a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative. It effectively reduces the peak amplitude of Nav1.2 currents with an IC50 value of 7.79 μM. This compound demonstrates significant antiepileptic properties, exhibiting a potent anticonvulsant effect while maintaining low neurotoxicity in subcutaneous pentetrazole-induced epilepsy models. It serves as a valuable tool for research in epilepsy and sodium channel modulation.
